OSRH
OSR Holdings, Inc.0.5536
-0.0238-4.12%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
14.21MP/E (TTM)
-Basic EPS (TTM)
-0.28Dividend Yield
0%Recent Filings
8-K
Vaximm VXM01 license term sheet
OSR Holdings' subsidiary Vaximm AG signed a non-binding term sheet on November 21, 2025, with BCM Europe AG—its largest shareholder—for a potential global license of the VXM01 oral cancer immunotherapy platform. Terms outline $20M upfront and up to $815M in milestones, plus royalty pass-through after BCME recovers any milestone delta from a future pharma partner. Non-binding beyond 120-day exclusivity. Deal hinges on definitive agreement.
10-Q
Q3 FY2025 results
OSR Holdings posted Q3 net sales of $627.7K, down 24% y/y yet gross profit climbed 46% to $261.7K on RMC's shift to a consignment model that slashed cost of sales 43% (derived). Operating loss widened slightly to $3.8M while net loss narrowed to $3.2M, with the net-operating gap driven by $685K other expenses including fair-value changes. Cash swelled to $2.2M on $5.2M financing inflows, against $3.3M operating burn YTD; short-term borrowings hit $1.9M. Business combination closed Feb 2025 via equity swap, no goodwill recorded per ASC 805. Nasdaq bid price lags below $1.00.
8-K
OSRH acquires noninvasive glucose tech
OSR Holdings' subsidiary OSRK signed a share exchange agreement on October 13, 2025, to acquire Woori IO, a South Korea-based developer of needle-free glucose monitoring via near-infrared spectroscopy, for KRW 15 billion (USD 10.6 million). This bolsters OSRH's medical-device portfolio with WORIO's Samsung-backed tech, targeting the $40+ billion global market by 2030, while enabling digital health integrations. Closing awaits approvals, eyed for January 12, 2026. Contingent conversion to OSRH stock hinges on hitting $10 per share within three years.
8-K
Stockholders elect 7 directors
OSR Holdings stockholders overwhelmingly elected seven directors—Kuk Hyoun Hwang, Jun Chul Whang, Alcide Barberis, Seng Chin Mah, Hyuk Joo Jee, Joong Myung Cho, and Reto Fierz—at the September 17, 2025 annual meeting, rejecting Jin Whan Park and Phil Geon Lee amid massive withhold votes. Shareholders also approved executive compensation, equity plan, and Nasdaq 20% issuance proposals with 61.73% quorum. Board refresh signals governance shift.
8-K
Chardan sues OSR Holdings
Chardan Capital Markets sued OSR Holdings and executive Kuk Hyoun Hwang on September 2, 2025, in New York federal court, demanding about $2,070,000 plus 34,500 shares of deferred equity over previously disclosed SEC matters. The company plans a vigorous defense. This litigation adds uncertainty to operations.
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
OBIO
Orchestra BioMed Holdings, Inc.
4.46+0.16
OCEA
Ocean Biomediacal, Inc.
0.00+0.00
OMER
Omeros Corporation
8.77-0.43
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OSTX
OS Therapies Incorporated
1.62-0.05
SONN
Sonnet BioTherapeutics Holdings
1.26-1.84
VKTX
Viking Therapeutics, Inc.
35.72-0.43
VXRT
Vaxart, Inc.
0.37+0.01